Species distribution and antifungal susceptibility patterns of candida species: Is low susceptibility to itraconazole a trend in Malaysia?

Medical Journal of Malaysia

Volumn 68, Issue 4, 2013, Pages 343-347

  Santhanam, Jacinta ^a   Yahaya, Nazmiah ^b   Aziz, Muhammad Nazri ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Antifungal; Candida; Itraconazole; Malaysia; Susceptibility

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA SAKE; CANDIDA TROPICALIS; CANDIDIASIS; CHILD; COLORIMETRY; CONTROLLED STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PICHIA ANOMALA; SPECIES DISTRIBUTION; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; ITRACONAZOLE; MALAYSIA; MICROBIAL SENSITIVITY TESTS;

EID: 84886884784     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Tortorano AM, Kibbler C, Perman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-66.
3. Chen PL, Lo HJ, Wu CJ, et al. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006. Mycoses 2011; 54: e17-e23.
4. Pfaller MA, Diekema DJ. Twelve years of Fluconazole in clinical practice: global trends in species distribution and Fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10: 11-23.
5. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-59.
6. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to Fluconazole and Voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-45.
7. Tzar MN, Shamim AS. Candidaemia and antifungal susceptibility testing in a teaching hospital. Med J Malaysia. 2009; 64(1): 61-64.
8. Pfaller MA, Diekema DJ. Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012. J Clin Microbiol 2012; 50(9): 2846-56.
9. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-89.
10. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A3 (3rd ed). Wayne: Clinical and Laboratory Standards Institute, 2008.
11. Bedini A, Venturelli C, Mussini C, et al. Epidemiology of candidaemia and antifungal susceptibility pattern in an Italian tertiary-care hospital. Clin Microbiol Infect 2006; 12: 75-80.
12. Tan TY, Tan AL, Tee NWS. A retrospective analysis of antifungal susceptibilities of Candida Bloodstream isolates from Singapore Hospital. Ann Acad Med. 2008; 37(10): 835-40.
13. Avolio M, Grosso S, Bruschetta G, Rosa RD, Camporese A. Direct antifungal susceptibility testing of positive Candida blood cultures by Sensititre YeastOne. New Microbiol 2009; 32: 179-84.
14. Lagrou K, Verhaegen J, Peetermans WE, Rijdt TD, Wijngaerden WV. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Clin Microbiol Infect Dis 2007; 26: 541-47.
15. Ng, KP, Saw TL, Na SL, Soo HTS. Systemic Candida infection in University Hospital 1997-1999: the distribution of Candida biotypes and antifungal susceptibility patterns. Mycopathologia 2000; 149: 141-46.
16. Pfaller MA. New developments in the antifungal susceptibility testing of Candida. Curr Fungal Infect Rep 2008; 2: 125-33.
17. Lombardi G, Farina C, Andreoni S, et al. Comparative evaluation of Sensititre YeastOne vs. the NCCLS M27A protocol and E-test for antifungal susceptibility testing of yeasts. J Clin Microbiol 2004; 47: 397-401.
18. Alexander BD, Byrne TC, Smith KL, et al. Comparative evaluation of Etest and Sensititre YeastOne Panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007; 45: 698-706.
19. Kim SH, Shin JH, Kim EC, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2007; 47: 296-304.
20. Kucharíková S, Van Dijck P, Lisalová M, Bujdáková H. Effect of antifungals on Itraconazole resistant Candida glabrata. Cent Eur J Biol 2010; 5: 318-23.
21. Amran F, Aziz MN, Ibrahim HM, et al. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol 2011; 60: 1312-16.
22. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125 (Suppl 1): S3-S13.